Parkinson’s disease (PD) affects about 10 million people worldwide, and cases are expected to double by 2050. Yet there is still no cure. Because we lack objective tools to monitor disease biology, it is difficult to assess new treatments, and diagnosis often arrives after irreversible brain damage has occurred.
Our answer to this problem is the FibrilRuler Test: a simple biomarker assay that measures amyloid fibrils, the key pathological hallmark of PD, directly in blood or spinal fluid. We detect their presence and quantify their properties to enable earlier detection and more accurate monitoring.
Our goal is to bridge the gap in PD diagnostics. Through the Biotech Booster program, we will validate the assay on retrospective patient samples and advance FibrilRuler to a clinic-ready test. By tracking PD earlier and more objectively, the assay supports therapy development, helps patients receive the right care sooner, and reduces the overall burden on healthcare systems.
